Clinical Trial Update: A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD" [Phase 2]

View source ↗

Summary

This is a Phase 2 trial evaluating radiotherapy-induced immune priming to enhance Elranatamab in relapsed/refractory multiple myeloma with extramedullary and pa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extramedullary Disease in Multiple Myeloma
• Multiple Myeloma
• Paramedullary Disease

Drugs mentioned

• Elranatamab (elranatamab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Phase 2, Radiotherapy-Induced Immune Priming | Phase 2 | Status: RECRUITING